| abstract |
(57) [Problem] To provide an erythropoietin complex having high in vivo bioactivity and expected to have excellent clinical efficacy. SOLUTION: It has at least one free amino group, Demonstrated in vivo bioactivity to increase reticulocyte and erythrocyte production in bone marrow cells, with human erythropoietin and 1 An erythropoietin glycoprotein selected from the group consisting of a human erythropoietin sequence modified by the addition of up to 6 glycosylation sites or the transposition of at least one glycosylation site and a poly (ethylene glycol). The conjugate is unmodified EPO and conventional PEG-EP It was found to have increased circulating half-life and plasma residence time, decreased clearance, and increased in vivo clinical activity compared to the O-complex. |